Cholesterol: new investigational combination pill

Patients treated with a new investigational combination pill showed significant improvements in cholesterol, triglycerides and other key lipids that lead to heart disease.
Simcor combines prescription niacin and simvastatin, two FDA-approved medications with established safety profiles, to target good cholesterol (HDL), bad cholesterol (LDL), and triglycerides in a single pill.
Treatment of high cholesterol has historically centered on the use of statins, including simvastatin, to lower LDL cholesterol, which has been the primary target of therapy.

Patients in the study treated with a Simcor combination containing 20 mg simvastatin had significantly better reductions in non-HDL (total cholesterol minus HDL) compared to 20 mg simvastatin therapy alone, as well as significant improvements in HDL and triglyceride levels. Patients receiving a Simcor combination with 40 mg simvastatin experienced reductions in non-HDL comparable to 80 mg high-dose simvastatin alone, and significant improvements in HDL and triglycerides.